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Abstract
Background: We aimed to evaluate urinary MCP-1 and oxidative stress through urinary malondialdehyde (MDA) in
leprosy and correlate them with traditional, but less sensitive markers of renal disease.
Methods: This is a cross-sectional study of 44 patients with diagnosis of leprosy and no previous treatment. Skin
smear was assessed through a bacteriological index - from 0 to 6+. Glomerular filtration rate (GFR), protein excretion
rate, microalbuminuria, urinary oxidative stress, malondialdehyde (MDA) and urinary MCP-1 were measured. Also,
high- sensitivity C-reactive protein (hs-CRP) was measured in the blood. Fifteen healthy subjects composed a
control group.
Results: Age and gender were similar between leprosy patients and control groups. No patient had a GFR < 60 mL/min/
1.73 m2 or albumin excretion rate greater than 30 mg/g-Cr. Leprosy patients had higher urinary protein excretion (97.6 ±
69.2 vs. 6.5 ± 4.3 mg/g-Cr, p < 0.001), urinary MCP-1 (101.0 ± 79.8 vs. 34.5 ± 14.9 mg/g-Cr, p = 0.006) and urinary MDA levels
(1.77 ± 1.31 vs. 1.27 ± 0.66 mmol/g-Cr, p = 0.0372) than healthy controls. There was a positive correlation between urinary
MCP-1 and bacteriological index in skin smears (r = 0.322, p = 0.035), urinary protein excretion (r = 0.547, p < 0.001),
albumin excretion rate (r = 0.414, p = 0.006) and urinary MDA (r = 0.453, p = 0.002). After adjusting for hs-CRP,
urinary MCP-1 remained correlated with albumin excretion rate (rpartial = 0.483, p = 0.007) and MDA levels
(rpartial = 0.555, p = 0.001).
Conclusion: Leprosy patients with no clinical kidney disease have increased urinary MCP-1 mainly in lepromatous polar
form. Inflammatory (MCP-1) and oxidative stress markers suggest leprosy patients are at high risk of developing
kidney disease.
Background
Leprosy, a chronic infectious disease caused by the
obligate intracellular bacterium Mycobacterium leprae,
remains a major source of morbidity in developing
countries. The disease affects mainly the skin and per-
ipheral nervous system, but it has a wide range of
clinical and histopathological manifestations. Depending
on the degree and efficacy of cell-mediated immunity,
patients can present with a single, well-demarcated le-
sion - polar tuberculoid (TT) or, on the other extreme,
with numerous, poorly demarcated, raised or nodular
lesions on all parts of the body, which constitutes polar
lepromatous (LL) leprosy. Other patients, however, fall
into a broad borderline category between these two
polar forms; this is subdivided into borderline leproma-
tous (BL), mid-borderline (BB), and borderline tubercu-
loid (BT) [1,2].
Renal lesions in leprosy patients can be present in up
to 72% of leprosy patients in autopsied patients [3]; how-
ever, clinical manifestation can be subtle. Only a few pa-
tients show a fast decline in renal function or major
proteinuria associated with edema. These uncommon
cases are published as case reports, due to their rarity
[4,5]. Many other leprosy patients can be at risk for de-
veloping kidney disease. Identification of these patients
is difficult in part due to lack of sensitivity of diagnostic
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tests used in clinical practice to detect incipient renal
disease.
The monocyte chemotactic protein-1 (MCP-1) is one
of the new recently studied renal biomarkers. This pro-
tein is expressed in injury and inflammation sites and
directs the recruitment of macrophages, which bind to
chemokine receptors to promote macrophage adhesion
and chemotaxis. The renal increase in MCP-1 expression
can occur in progressive kidney disease and when there
is interstitial inflammatory infiltrate [6]. Urinary MCP-1
has been associated with increased albuminuria in pa-
tients with other renal diseases, such as diabetes [7].
Also, investigations suggest that oxidative stress plays a
pivotal role in the pathogenesis, progression, and complica-
tions of kidney disease [8]. Several urinary biomarkers of
oxidative stress have been studied in the context of progres-
sive kidney disease [9,10].
In the present study, we aimed to evaluate urinary
MCP-1 and oxidative stress through urinary malondial-
dehyde (MDA) in leprosy patients in comparison with a
healthy control group and correlate them with traditional,
but less sensitive markers of renal disease. In addition, we
compared patients according to bacilli smear positive
cases and polar leprosy clinical picture.
Methods
This is a cross-sectional study of 44 patients with clinical
and laboratory diagnosis of leprosy. Data were collected
among patients diagnosed with leprosy with no previous
anti-mycobacterium treatment. Patients were recruited
in public health centers from Fortaleza, state of Ceara,
Brazil between August 2012 and August 2013. This
study protocol was approved by the Ethical Committee
of Walter Cantidio University Hospital, Universidade
Federal do Ceara, Brazil (N. 267.426) and all participants
signed informed consent. Exclusion criteria included: pa-
tients with known previous renal disease (according to
Kidney Disease Outcomes Quality Initiative recommen-
dations - glomerular filtration rate higher than 60 mL/
min/1.73 m [2] and albumin excretion rate less than
30 mg/g-Cr), diabetes mellitus, systemic lupus erythema-
tosus, arterial hypertension and erythema nodosum
leprosum reaction episode. Also, a group of 15 healthy
subjects were included as a control group.
The following data were collected: age, gender, time of
symptoms, use of other concomitant drugs, number of
skin lesions, skin smear microscopy, systolic and dia-
stolic blood pressure. Leprosy was classified clinically as
tuberculoid polar form (TT and BT), mid-borderline
(BB) and lepromatous polar form (BL and LL). Also, pa-
tients were classified regarding smear-positivity as pauciba-
cillary (no bacilli smear-positive) or multibacillary. Skin
smear was assessed through a bacteriological index - from
0 to 6+ [2]. Serum creatinine and high-sensitivity
C-reactive protein (hs-CRP) were measured. Additionally,
a morning urine sample (after approximately an 8-hour
fasting period) was collected and creatinine, total protein,
microalbuminuria, MDA and MCP-1 levels were measured.
All urine measurements were normalized by urinary cre-
atinine concentration. Glomerular filtration rate (GFR) was
estimated using CKD-EPI equation.
The analytical methods used for creatinine and urine pro-
tein excretion, measurement were colorimetric methods
(Labtest®). C-reactive protein (CRP) and microalbuminuria
were quantified by automated immunoturbidimetry (Cobas
C 111, Roche®). Urinary malondialdehyde (MDA) was iso-
lated and quantified using the thiobarbituric acid (TBARS)
test. Urinary MCP-1 was determined by sandwich enzyme-
linked immunosorbent assay (ELISA) (Boster Biological
Technology, Fremont, CA, USA).
Data were tested for normal distribution and are shown
as mean ± S.D. Groups were compared using t-student test
or one-way-ANOVA with Bonferroni post-test. Correla-
tions were performed using Pearson’s coefficient. A p-value
less than 0.05 was considered significant.
Results
A total of 44 patients (63.6% males) with a mean age
of 36.1 ± 10.6 years old were selected. Additionally, 15
healthy patients were selected as controls - mean age
35.4 ± 9.2. Time from symptom onset to leprosy diagno-
sis ranged from one month to 8 years, with a median
time of 17 months. Twenty-six patients had positive
skin-smear test (multibacillary – MB) and 18 were pau-
cibacillary - PB. Clinically, there were 14 TT/BT, 19 BB
and 11 LL/BL leprosy patients. Regarding renal function,
no patient had chronic kidney disease according to Kidney
Disease Outcomes Quality Initiative definition - glomerular
filtration rate higher than 60 mL/min/1.73 m [2] and albu-
min excretion rate less than 30 mg/g-Cr.
Leprosy patients had higher urinary MCP-1 (101.0 ± 79.8
vs. 34.5 ± 14.9 mg/g-Cr, p = 0.006) and urinary MDA levels
(1.77 ± 1.31 vs. 1.27 ± 0.66 mmol/g-Cr, p = 0.0372) than
healthy controls. Also, urinary protein excretion was higher
in leprosy patients when compared to controls (97.6 ± 69.2
vs. 6.5 ± 4.3 mg/g-Cr, p < 0.001). Moreover, there was a
stepwise increment in urinary MCP-1 and urine protein ex-
cretion rate values from tuberculoid to lepromatous type in
leprosy patients – see Figure 1. Urinary MCP-1 was higher
in multibacillary than in paucibacillary patients (122.1 ±
91.9 vs. 72.0 ± 46.1 mg/g-Cr, p = 0.023) and there was a
positive correlation between urinary MCP-1 and bacterio-
logical index in skin smears (r = 0.322, p = 0.035). No sig-
nificant correlation between urinary MCP-1 and time of
symptoms was observed (r = 0.014, p = 0.938).
Although there was no correlation between glomerular
filtration rate and urinary MCP-1 levels (r =−0.018, p =
0.906), urinary MCP-1 was correlated with urinary protein
Meneses et al. BMC Infectious Diseases 2014, 14:451 Page 2 of 5
http://www.biomedcentral.com/1471-2334/14/451
excretion (r = 0.547, p < 0.001), albumin excretion rate
(r = 0.414, p = 0.006) and urinary MDA (r = 0.453, p =
0.002) – Figure 2. To exclude the possibility that elevated
urinary MCP-1 would be only a reflex of systemic inflam-
mation, we also measured serum hs-CRP and there was no
correlation between both markers (r = −0.095, p = 0.606).
After adjusting for hs-CRP, urinary MCP-1 remained corre-
lated with albumin excretion rate (rpartial = 0.483, p = 0.007)
and MDA levels (rpartial = 0.555, p = 0.001) – Table 1.
Discussion
In the present study, leprosy patients with no clinical
kidney disease had increased urinary MCP-1 and MDA,
new markers of kidney disease progression. Moreover,
patients with multibacillary and lepromatous polar form
of leprosy had increased levels of urinary MCP-1. Albumin
excretion rate, a known marker of kidney disease progres-
sion, correlated with urinary MCP-1. Also, there was a posi-
tive correlation between urinary MCP-1 and MDA.
Leprosy patients can present with kidney disease of
glomerular (glomerulonephritis/amyloidosis) or tubule-
interstitial etiology. Generally, these patients present
clinically with overt proteinuria or reduced GFR. Al-
though they have been well described, these pathologies
are not common and are generally published as case re-
ports. However, leprosy patients have an increased risk
of developing chronic kidney disease and subclinical
renal lesions can be a common event [11]. In this study,
leprosy patients with no clinical kidney disease showed
increased levels of urinary MCP-1. This is a relatively
Figure 1 Urinary MCP-1 and protein excretion in controls and leprosy patients according their clinical classification.
Figure 2 Pearson correlations between number bacteriological
index in skin smear, urinary monocyte chemotactic protein-1
(MCP-1), urinary malondialdehyde and urine albumin excretion.
*p < 0.05, **p < 0.01.
Table 1 Pearson and partial correlation between MCP-1








−0.018 0.906 0.002 0.934
Urinary protein
excretion
0.547 <0.001 0.526 0.002
Albumin excretion
rate
0.414 0.006 0.483 0.007
Urinary MDA 0.453 0.002 0.555 0.001
Hs-CRP: high-sensibility C-reactive protein; MDA: malondialdehyde.
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new biomarker that has been associated with kidney dis-
ease progression in other pathologies, such as diabetic
nephropathy. Although patients with active lupus neph-
ritis [12] had higher urinary MCP-1 levels than leprosy
patients; these had urinary MCP-1 level comparable to
diabetic patients with microalbuminuria [13].
Interestingly, urinary MCP-1 levels were correlated
with the lepromatous polar form and the bacteriological
index in skin smears. This correlation is probably due to
increased immunocomplexes in renal disease in multiba-
cillary patients, resulting in higher inflammation burden.
However, we cannot exclude the possibility that a pre-
dominant Th2 immune response can be responsible for
renal inflammation in these patients. Monocyte chemo-
attractant protein–1 has been recognized as a crucial
factor for the development of adaptive Th2 responses
[14], making the second hypothesis plausible.
Urinary oxidative stress was increased in leprosy patients
and correlated with urinary MCP-1 levels. Recently, kidney
MCP-1 expression was correlated with oxidative stress in
diabetic nephropathy [15]. According to Figure 2, we sug-
gest that increased MCP-1 levels increase renal oxidative
stress, contributing to renal damage.
Both urinary MCP-1 and oxidative stress correlated
with urinary protein and albumin excretion rate. Urinary
albumin excretion rate is a known marker of kidney dis-
ease progression and studies have indicated a continuous
risk increment with high levels of urinary albumin excre-
tion, even when it remains within the normal range [16].
This fact indicates that leprosy patients can be at risk of
developing advanced renal disease in the future. Consid-
ering that more than 15% of leprosy patients can show
elevated urine albumin excretion [17], urinary MCP-1
can be a useful early biomarker to identify patients at
risk. Although, leprosy is not a recognized cause of clin-
ical kidney disease, it may be due to the long time to
developing chronic kidney damage. It is probable that a
long-term follow-up in leprosy patients can detect a
higher incidence of chronic kidney disease in compari-
son with normal population.
The possibility that urinary MCP-1 was only a mani-
festation of systemic inflammation was considered,
but even after adjusting for hs-CRP, urinary MCP-1
remained correlated with urine albumin and protein
excretion rates, indicating that renal MCP-1 expres-
sion is increased in these patients, regardless of sys-
temic inflammation.
The main limitation of the present study is its cross-
sectional design. Because of its design, we cannot affirm
there is a causal relationship between urinary MCP-1,
oxidative stress and urinary albumin excretion. Also, co-
hort prospective studies are necessary to determine
whether these subclinical renal alterations will develop
into the clinically manifest disease.
Conclusion
We demonstrated that leprosy patients with no clinical
kidney disease have increased urinary MCP-1 and its
levels are even higher in patients with the lepromatous
polar form. Moreover, urinary MCP-1 was associated
with urinary oxidative stress and urinary albumin excre-
tion, suggesting these patients are at increased risk of
developing clinical kidney disease.
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